



Proven prevention.

Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3):
a multicentre randomised controlled trial.

Primary Objective


- Determine the effectiveness of IPC to reduce the risk of DVT in patients who have had a stroke

Materials & Methods

- Multicentre, randomised, controlled trial of 2,876 patients at 105 centres within the United Kingdom
- Compression Duplex Ultrasound (CDU) of both legs was to be performed by a technician blinded to treatment allocation at 7-10 days and when possible, 25-30 days after enrolment
- Adverse events, including falls associated with significant injury or damage to the skin of the legs, were recorded

Investigator Conclusions

- IPC is effective in reducing the risk of both proximal, symptomatic and "any DVT" in immobile patients who have had a stroke.
- Adverse effects due to the use of IPC were rare
- The CLOTS 3 data provide robust evidence for the effectiveness of IPC in the prevention of DVT and it possibly improves survival in patients who are initially immobile



Powerful results. Proven prevention.

Cardinal Health Kendall SCD™ technology with Vascular Refill Detection delivers sequential, circumferential, graduated compression to decrease the risk of venous thrombosis by reducing stasis and stimulating the release of intrinsic fibrinolytic substances. This addresses two of the three factors in Virchow's triad.

Vascular Refill Detection technology, which customises the compression cycle to the individual patient, is clinically proven to move more blood over time while reducing stasis.²

References


1. Dennis MS, et al. Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. The Lancet. Published online: 31 May, 2013.
2. Kakkos SK et al. The efficacy of the new SCD Response Compression System in the prevention of venous stasis. Journal of Vascular Surgery 2000;32:932-40.

For healthcare professionals only. Important information: Prior to use, refer to the instructions for use supplied with this device for indications, contraindications, side effects, suggested procedure, warnings and precautions. As part of its continuous product development policy, Cardinal Health reserves the right to change product specifications without prior notification. Please contact your Cardinal Health representative for additional product availability information. © 2019 Cardinal Health. All Rights Reserved. CARDINAL HEALTH, Cardinal Health LOGO, ESSENTIAL TO CARE and KENDALL SCD are trademarks of Cardinal Health and may be registered in the US and/or in other countries. 2MP19-922273 (03/2019)



Primary outcomes

Proximal DVT at 30 days
(Popliteal/Femoral) $p = 0.001$




Secondary outcomes

Mortality Risk Reduction



The rate of mortality during the first six months was 15% lower with the IPC Group compared to the non-IPC Group. (Adjusted hazard ratio = 0.86; $p = 0.042$)

DVT Events



The **secondary outcomes within 30 days** were: death, any DVT, pulmonary embolism confirmed on imaging or autopsy, complications of IPC

The **secondary outcomes at 6 months** were: death from any cause and any confirmed symptomatic or asymptomatic DVT or pulmonary embolism occurring since randomisation. Other secondary outcomes measured at 6 months included: place of residence; functional status and health related quality of life and symptoms of possible post phlebotic leg syndrome (eg, leg swelling or ulcers).